(Q51580972)

English

Tumor growth modeling from clinical trials reveals synergistic anticancer effect of the capecitabine and docetaxel combination in metastatic breast cancer.

scientific article published on 8 April 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21476101%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

Tumor growth modeling from clinical trials reveals synergistic anticancer effect of the capecitabine and docetaxel combination in metastatic breast cancer (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21476101%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21476101%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

author name string

N Frances

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21476101%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

L Claret

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21476101%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

A Iliadis

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21476101%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

publication date

8 April 2011

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21476101%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

Cancer Chemotherapy and Pharmacology

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21476101%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

68

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21476101%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21476101%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

1413-1419

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21476101%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

https://scigraph.springernature.com/pub.10.1007/s00280-011-1628-6

0 references

Modeling of tumor growth and anticancer effects of combination therapy

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1628-6

21 January 2018

Testing additivity of anticancer agents in pre-clinical studies: a PK/PD modelling approach

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1628-6

21 January 2018

Erlotinib and bevacizumab have synergistic activity against melanoma

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1628-6

21 January 2018

Preclinical pharmacokinetic/pharmacodynamic models to predict synergistic effects of co-administered anti-cancer agents

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1628-6

21 January 2018

Capecitabine: a review

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1628-6

21 January 2018

Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1628-6

21 January 2018

Diversity of mechanism-based pharmacodynamic models

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1628-6

21 January 2018

A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1628-6

21 January 2018

Individualised cancer chemotherapy: strategies and performance of prospective studies on therapeutic drug monitoring with dose adaptation: a review

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1628-6

21 January 2018

A pharmacodynamic model for the time course of tumor shrinkage by gemcitabine + carboplatin in non-small cell lung cancer patients.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1628-6

21 January 2018

Magnitude of response with myeloma frontline therapy does not predict outcome: importance of time to progression in southwest oncology group chemotherapy trials

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1628-6

21 January 2018

Optimizing drug regimens in cancer chemotherapy by an efficacy-toxicity mathematical model.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1628-6

21 January 2018

Identifiers

10.1007/S00280-011-1628-6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21476101%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21476101%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51580972&oldid=1577698277"